Mercury Pharmaceuticals UK

Jan 2026

New medical LLM detects depression in women via WhatsApp audio analysis

A new medical large language model (LLM) achieved over 91 percent accuracy in identifying female participants diagnosed with major depressive disorder after analyzing a short WhatsApp audio recording where participants described their week, according to a study published January 21, 2026 in the open-access journal PLOS Mental Health by Victor H. O. Otani, from Santa Casa de São Paulo School of Medical Sciences and Infinity Doctors Inc., Brazil, and colleagues.

Jan 2026

Lifelong health: The Northern Finland Birth Cohort 1966 enters a new era of aging research

One of the world’s most extensive birth cohorts is now entering later adulthood. At the University of Oulu in Finland, the Northern Finland Birth Cohort 1966 (NFBC1966) is launching a major new follow-up combining decades of biological, social, and environmental data with modern digital health tools to examine how lifelong exposures and the genome shape health and aging.

Jan 2026

Bedfont® Scientific Limited is pleased to support a major milestone to improve asthma care

Bedfont® Scientific Limited, a medical device manufacturer based in Kent, with over 49 years’ experience in the breath analysis industry, was pleased to support its UK distributor, Intermedical UK, in supplying the 3,000th NObreath® Fractional exhaled Nitric Oxide (FeNO) device in the UK.

Jan 2026

Unlocking microbial secrets for health on Earth and beyond

Microorganisms live in biofilms - the equivalent of microbial "cities"- everywhere on Earth. These city-like structures protect and house microbial communities and play essential roles in enabling human and plant health on our planet.

Jan 2026

Sperm RNA aging shift that may explain paternal age effects

Study reveals an 'aging cliff' in sperm RNA, linking age-related changes to early development and highlighting risks associated with advanced paternal age.

Jan 2026

Study identifies a powerful strategy to overcome drug resistance in breast cancer

A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Communications, identifies a powerful strategy to overcome drug resistance in breast cancer by simultaneously targeting two key cell-cycle regulators, CDK2 and CDK4/6.